Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells 29,643 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Julie Green sold 29,643 shares of Invivyd stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total transaction of $16,896.51. Following the completion of the transaction, the insider owned 49,344 shares of the company’s stock, valued at $28,126.08. This represents a 37.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Julie Green also recently made the following trade(s):

• On Monday, August 18th, Julie Green sold 20,013 shares of Invivyd stock. The shares were sold at an average price of $0.65, for a total transaction of $13,008.45.

Invivyd Trading Up 11.0%

Invivyd stock opened at $0.6338 on Thursday. Invivyd, Inc. has a 1-year low of $0.3546 and a 1-year high of $2.74. The firm has a market capitalization of $76.14 million, a price-to-earnings ratio of -0.69 and a beta of 0.51. The firm has a 50 day simple moving average of $0.74 and a 200 day simple moving average of $0.83.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). Invivyd had a negative net margin of 238.33% and a negative return on equity of 177.89%. The business had revenue of $11.79 million during the quarter, compared to analysts’ expectations of $23.16 million. On average, equities research analysts forecast that Invivyd, Inc. will post -1.64 EPS for the current year.

Hedge Funds Weigh In On Invivyd

A number of hedge funds and other institutional investors have recently bought and sold shares of IVVD. JPMorgan Chase & Co. grew its stake in Invivyd by 644.1% in the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock worth $114,000 after buying an additional 222,375 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Invivyd in the 4th quarter worth approximately $74,000. Barclays PLC grew its stake in Invivyd by 7.8% in the 4th quarter. Barclays PLC now owns 127,180 shares of the company’s stock worth $56,000 after buying an additional 9,207 shares in the last quarter. Jane Street Group LLC grew its stake in Invivyd by 290.5% in the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock worth $52,000 after buying an additional 87,358 shares in the last quarter. Finally, Deutsche Bank AG grew its stake in Invivyd by 35.2% in the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company’s stock worth $385,000 after buying an additional 227,463 shares in the last quarter. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on IVVD shares. D. Boral Capital reduced their price objective on shares of Invivyd from $9.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Invivyd in a research note on Thursday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $3.85.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.